Verition Fund Management
JANX icon

Verition Fund Management’s Janux Therapeutics JANX Stock Holding History

Verition Fund Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,731
Closed -$995K – 3714
2025
Q3 		$995K Buy
40,731
+28,761
+240% +$700K ﹤0.01% 2542
2025
Q2 		$277K Buy
+11,970
New +$315K ﹤0.01% 3238
2025
Q1 		– Sell
-5,618
Closed -$301K – 3513
2024
Q4 		$301K Buy
+5,618
New +$297K ﹤0.01% 2782

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Verition Fund Management's JANX Position: Q4 2025 in Review

Verition Fund Management sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 40,731 shares — an estimated $995K sold.

Verition Fund Management first reported a position in JANX in Q4 2024 and held it in 3 quarters. The position peaked at $995K in Q3 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Verition Fund Management reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 40,731 Janux Therapeutics shares in Q4 2025, an estimated $995K.
  • Verition Fund Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 3 quarters.
  • Verition Fund Management's Janux Therapeutics position peaked at $995K in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.